Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN

Rhea-AI Summary

Catheter Precision (NYSE American:VTAK) presented new clinical data from the VIVO EU Registry at the Society of Cardiac Robotic Navigation meeting in Lisbon. Professor Leonor Parreira shared final data from Hospital da Luz, involving 27 subjects, of which 18 underwent ablation procedures. The results showed 100% accurate identification of site origin, approximately 95% successful ablation procedures, and 83% of patients remained arrhythmia-free at 12 months post-ablation. The company plans to publish complete study results including data from seven additional studies.

Positive

• 100% accuracy in identifying cardiac segment origin
• 95% success rate in ablation procedures
• 83% of patients remained arrhythmia-free after 12 months
• First study with 12-month post-ablation follow-up data

Negative

• None.

FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.

As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:

• 100% accurate identification of the site of origin to the exact or neighboring cardiac segment

• 17 (≈95%) patients had successful ablation procedures

• 83% of patients had no recurrence of the arrhythmia at 12 months post ablation

"100% accuracy continues to impress our current physicians while attracting new physicians, and we look forward to publishing the complete study results which will include data from seven additional studies", said David Jenkins, CEO of Catheter Precision. "VIVO has always proven to be accurate in clinical studies, but this is the first study where we have assessed patients at 12 months post ablation. This data is the first step in understanding how VIVO can impact not only the success of the ablation procedure but improve the decision making about moving forward with an ablation procedure and potentially the long-term outcomes for future patients."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com

# # #

Contact Information

Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000

SOURCE: Catheter Precision, Inc.

View the original press release on accesswire.com

FAQ

What were the success rates of VTAK's VIVO system in the Hospital da Luz study?

The VIVO system showed 100% accuracy in identifying site origin, 95% success in ablation procedures, and 83% of patients remained arrhythmia-free after 12 months.

How many patients were included in VTAK's Hospital da Luz VIVO study?

The study enrolled 27 subjects, of which 18 proceeded with ablation procedures.

When and where was the new VTAK VIVO clinical data presented?

The data was presented at the Society of Cardiac Robotic Navigation meeting in Lisbon, Portugal, on October 28-29, 2024.

What is the significance of VTAK's latest VIVO study results?

This is the first study to assess patients at 12 months post-ablation, providing insights into long-term outcomes and procedure decision-making effectiveness.